| Primary |
| Macular Degeneration |
58.5% |
| Ill-defined Disorder |
11.0% |
| Age-related Macular Degeneration |
8.2% |
| Diabetic Retinal Oedema |
6.9% |
| Choroidal Neovascularisation |
4.7% |
| Macular Oedema |
3.3% |
| Drug Use For Unknown Indication |
1.4% |
| Maculopathy |
1.4% |
| Diabetic Retinopathy |
0.8% |
| Diabetic Neuropathy |
0.5% |
| Neovascularisation |
0.5% |
| Retinal Vein Occlusion |
0.5% |
| Anaesthesia |
0.3% |
| Blindness |
0.3% |
| Electromechanical Dissociation |
0.3% |
| Hypertension |
0.3% |
| Myocardial Infarction |
0.3% |
| Neuritis |
0.3% |
| Pain |
0.3% |
| Product Used For Unknown Indication |
0.3% |
|
| Visual Acuity Reduced |
18.4% |
| Endophthalmitis |
11.4% |
| Retinal Haemorrhage |
11.4% |
| Myocardial Infarction |
6.0% |
| Intraocular Pressure Increased |
5.5% |
| Death |
5.0% |
| Cerebral Infarction |
4.0% |
| Sudden Death |
4.0% |
| Vitreous Haemorrhage |
4.0% |
| Visual Disturbance |
3.5% |
| Cerebrovascular Accident |
3.0% |
| Eye Pain |
3.0% |
| Hypersensitivity |
3.0% |
| Injection Site Pain |
3.0% |
| Vitritis |
3.0% |
| Discomfort |
2.5% |
| Eye Haemorrhage |
2.5% |
| Retinal Artery Occlusion |
2.5% |
| Visual Impairment |
2.5% |
| Drug Ineffective |
2.0% |
|
| Secondary |
| Drug Use For Unknown Indication |
29.4% |
| Diabetic Retinal Oedema |
26.5% |
| Choroidal Neovascularisation |
14.7% |
| Macular Degeneration |
14.7% |
| Age-related Macular Degeneration |
5.9% |
| Product Used For Unknown Indication |
5.9% |
| Off Label Use |
2.9% |
|
| Cerebrovascular Accident |
25.0% |
| Abscess Limb |
8.3% |
| Death |
8.3% |
| Macular Oedema |
8.3% |
| Pneumonia |
8.3% |
| Retinal Oedema |
8.3% |
| Visual Impairment |
8.3% |
| Abdominal Pain Upper |
4.2% |
| Cerebral Infarction |
4.2% |
| Detachment Of Retinal Pigment Epithelium |
4.2% |
| Retinal Pigment Epithelial Tear |
4.2% |
| Urinary Tract Infection |
4.2% |
| Urine Output Decreased |
4.2% |
|
| Concomitant |
| Drug Use For Unknown Indication |
31.3% |
| Product Used For Unknown Indication |
20.9% |
| Macular Degeneration |
10.4% |
| Age-related Macular Degeneration |
6.0% |
| Intra-ocular Injection |
4.5% |
| Rheumatoid Arthritis |
4.5% |
| Hypertension |
3.7% |
| Polypoidal Choroidal Vasculopathy |
3.7% |
| Arthralgia |
1.5% |
| Back Pain |
1.5% |
| Choroidal Neovascularisation |
1.5% |
| Constipation |
1.5% |
| Depression |
1.5% |
| Diabetes Mellitus |
1.5% |
| Hypercholesterolaemia |
1.5% |
| Mineral Supplementation |
1.5% |
| Osteoporosis |
1.5% |
| Pruritus |
1.5% |
|
| Swollen Tongue |
15.8% |
| Cerebrovascular Accident |
10.5% |
| Vitreous Haemorrhage |
10.5% |
| Cataract Subcapsular |
5.3% |
| Injection Site Pain |
5.3% |
| Mitral Valve Incompetence |
5.3% |
| Retinal Depigmentation |
5.3% |
| Retinal Haemorrhage |
5.3% |
| Urinary Incontinence |
5.3% |
| Vitrectomy |
5.3% |
| Angioneurotic Oedema |
2.6% |
| Atrial Fibrillation |
2.6% |
| Eye Pruritus |
2.6% |
| Foreign Body Sensation In Eyes |
2.6% |
| Gamma-glutamyltransferase Increased |
2.6% |
| Inappropriate Schedule Of Drug Administration |
2.6% |
| Nausea |
2.6% |
| Tachypnoea |
2.6% |
| Urinary Tract Infection |
2.6% |
| Vitreous Injury |
2.6% |
|
